search
Back to results

Managing Diabetes During Pregnancy in the Wireless Age

Primary Purpose

Gestational Diabetes Mellitus, Type 2 Diabetes Mellitus

Status
Unknown status
Phase
Not Applicable
Locations
Canada
Study Type
Interventional
Intervention
Home Blood Glucose Telemonitoring System
Sponsored by
Samuel Lunenfeld Research Institute, Mount Sinai Hospital
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Gestational Diabetes Mellitus

Eligibility Criteria

18 Years - 50 Years (Adult)FemaleDoes not accept healthy volunteers

Inclusion Criteria:

  • patients must be pregnant
  • diagnosed with gestational diabetes or Type 2 diabetes
  • must be comfortable with instructions in English and be able to express themselves using simple phrases in English.

Exclusion Criteria:

  • unable to complete self monitoring of blood glucose (SMBG) for any reason
  • uncomfortable with the use of the telemonitoring equipment
  • develop an acute illness requiring hospitalization, where they may deviate from the normal delivery of care
  • refusal to sign consent form or to carry out the demands made by the study

Sites / Locations

  • Mount Sinai Hospital, Leadership Sinai Centre for DiabetesRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

Telemonitoring

Usual Care

Arm Description

Outcomes

Primary Outcome Measures

Mean blood glucose, based on the highest post-prandial blood glucose reading for each day, by trimester
An average of 12 weeks.

Secondary Outcome Measures

Mean fasting and post-prandial blood glucose by trimester
An average of 12 weeks.
Percentage of values within recommended guidelines
An average of 12 weeks.
Adherence: Percentage of values recorded over expected number of values
An average of 12 weeks.
Adherence: Average number of values per day
An average of 12 weeks.
Onset of labour and mode of delivery
An average of 3 days.
Fetal outcomes: gestational age at delivery, birth weight (by gender), percentage of macrosomia, large for gestational age (LGA) and small for gestational age (SGA), APGAR at 1 and 5 minutes
An average of 1 day.
Perinatal complications (i.e. premature, NICU admission, jaundice, shoulder dystocia, hypoglycemia)
An average of 1 week.
Provider usage: number of logins onto the system, average amount of time spent on the system per week
An average of 12 weeks.

Full Information

First Posted
July 20, 2011
Last Updated
November 17, 2011
Sponsor
Samuel Lunenfeld Research Institute, Mount Sinai Hospital
Collaborators
Ontario Ministry of Health and Long Term Care
search

1. Study Identification

Unique Protocol Identification Number
NCT01474525
Brief Title
Managing Diabetes During Pregnancy in the Wireless Age
Official Title
Managing Diabetes During Pregnancy in the Wireless Age: a RCT of Glucose Telemonitoring
Study Type
Interventional

2. Study Status

Record Verification Date
November 2011
Overall Recruitment Status
Unknown status
Study Start Date
January 2010 (undefined)
Primary Completion Date
March 2012 (Anticipated)
Study Completion Date
March 2012 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Samuel Lunenfeld Research Institute, Mount Sinai Hospital
Collaborators
Ontario Ministry of Health and Long Term Care

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
This Randomized Controlled Trial (RCT) will test the efficacy of a home blood glucose telemonitoring system against usual care in women with gestational diabetes mellitus (GDM) or type 2 diabetes mellitus (T2DM) during pregnancy. We hypothesize that the system can improve glycemic control in patients, assessed using the mean blood glucose during gestation as the primary outcome measure.
Detailed Description
Establishing good glycemic control is crucial for the treatment of patients with gestational diabetes mellitus (GDM) and type 2 diabetes mellitus (DM2). High levels of blood glucose in pregnancy may lead to complications during delivery and pose threat to the fetus. The self-monitoring of blood glucose (SMBG) by patients at home is used to provide clinicians with information to make adjustments to treatment plans. Patients record the values and present them at their next meeting with the physician. As such, SMBG by the patients is an important part of disease management and a method for clinicians to follow a patient's day-to-day response to a treatment regime. The system is designed to send the blood glucose values from the patients' glucometers wirelessly to the server where they can be viewed by the patients' health care providers. The system generates automated adherence reminders to patients and alert messages to both patients and their care providers. The system will provide clinicians with better access to the patient data, so that they may better manage their case loads, make timely clinical decisions, and ultimately provide better patient care.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Gestational Diabetes Mellitus, Type 2 Diabetes Mellitus

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
100 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Telemonitoring
Arm Type
Experimental
Arm Title
Usual Care
Arm Type
Active Comparator
Intervention Type
Device
Intervention Name(s)
Home Blood Glucose Telemonitoring System
Intervention Description
The system is designed to send the measured blood glucose values directly to a hospital server. Values recorded by the glucometer are sent to the Blackberry® cell phone. A special removable Bluetooth® adapter unit is required for data transmission from the glucometer to the Blackberry®. The patient must then select on the Blackberry® the meal period the last measurement corresponds. The cellular phone serves as the platform for data-transmission to the central server. The threshold number of readings can be set for each patient individually through the web-interface. The system can be accessed by both the patients and the care providers through a secure web-interface. Apart from collecting values the system generates automated adherence reminders to patients and high/low blood glucose alert messages to both patients and their care providers.
Primary Outcome Measure Information:
Title
Mean blood glucose, based on the highest post-prandial blood glucose reading for each day, by trimester
Description
An average of 12 weeks.
Time Frame
from the baseline to the delivery date
Secondary Outcome Measure Information:
Title
Mean fasting and post-prandial blood glucose by trimester
Description
An average of 12 weeks.
Time Frame
from the baseline to the delivery date
Title
Percentage of values within recommended guidelines
Description
An average of 12 weeks.
Time Frame
from the baseline to the delivery date
Title
Adherence: Percentage of values recorded over expected number of values
Description
An average of 12 weeks.
Time Frame
from the baseline to the delivery date
Title
Adherence: Average number of values per day
Description
An average of 12 weeks.
Time Frame
from the baseline to the delivery date
Title
Onset of labour and mode of delivery
Description
An average of 3 days.
Time Frame
at exit (delivery)
Title
Fetal outcomes: gestational age at delivery, birth weight (by gender), percentage of macrosomia, large for gestational age (LGA) and small for gestational age (SGA), APGAR at 1 and 5 minutes
Description
An average of 1 day.
Time Frame
at exit (delivery)
Title
Perinatal complications (i.e. premature, NICU admission, jaundice, shoulder dystocia, hypoglycemia)
Description
An average of 1 week.
Time Frame
at exit (delivery)
Title
Provider usage: number of logins onto the system, average amount of time spent on the system per week
Description
An average of 12 weeks.
Time Frame
for the duration of the study

10. Eligibility

Sex
Female
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
50 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: patients must be pregnant diagnosed with gestational diabetes or Type 2 diabetes must be comfortable with instructions in English and be able to express themselves using simple phrases in English. Exclusion Criteria: unable to complete self monitoring of blood glucose (SMBG) for any reason uncomfortable with the use of the telemonitoring equipment develop an acute illness requiring hospitalization, where they may deviate from the normal delivery of care refusal to sign consent form or to carry out the demands made by the study
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Alexander G Logan, MD, FRCP(C)
Phone
416-586-5187
Email
logan@lunenfeld.ca
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Alexander G Logan, MD, FRCP(C)
Organizational Affiliation
MOUNT SINAI HOSPITAL
Official's Role
Principal Investigator
Facility Information:
Facility Name
Mount Sinai Hospital, Leadership Sinai Centre for Diabetes
City
Toronto
State/Province
Ontario
ZIP/Postal Code
M5T 3L9
Country
Canada
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Alexander G Logan, MD, FRCP(C)
Phone
416-586-5187
Email
logan@lunenfeld.ca
First Name & Middle Initial & Last Name & Degree
Alexander G Logan, MD, FRCP(C)

12. IPD Sharing Statement

Citations:
PubMed Identifier
18463375
Citation
HAPO Study Cooperative Research Group; Metzger BE, Lowe LP, Dyer AR, Trimble ER, Chaovarindr U, Coustan DR, Hadden DR, McCance DR, Hod M, McIntyre HD, Oats JJ, Persson B, Rogers MS, Sacks DA. Hyperglycemia and adverse pregnancy outcomes. N Engl J Med. 2008 May 8;358(19):1991-2002. doi: 10.1056/NEJMoa0707943.
Results Reference
background
PubMed Identifier
15951574
Citation
Crowther CA, Hiller JE, Moss JR, McPhee AJ, Jeffries WS, Robinson JS; Australian Carbohydrate Intolerance Study in Pregnant Women (ACHOIS) Trial Group. Effect of treatment of gestational diabetes mellitus on pregnancy outcomes. N Engl J Med. 2005 Jun 16;352(24):2477-86. doi: 10.1056/NEJMoa042973. Epub 2005 Jun 12.
Results Reference
background
PubMed Identifier
12020549
Citation
Feig DS, Palda VA. Type 2 diabetes in pregnancy: a growing concern. Lancet. 2002 May 11;359(9318):1690-2. doi: 10.1016/S0140-6736(02)08599-9. No abstract available.
Results Reference
background
PubMed Identifier
18297573
Citation
Langer O. Type 2 diabetes in pregnancy: exposing deceptive appearances. J Matern Fetal Neonatal Med. 2008 Mar;21(3):181-9. doi: 10.1080/14767050801929497.
Results Reference
background
PubMed Identifier
18191067
Citation
Kinsley B. Achieving better outcomes in pregnancies complicated by type 1 and type 2 diabetes mellitus. Clin Ther. 2007;29 Suppl D:S153-60. doi: 10.1016/j.clinthera.2007.12.015.
Results Reference
background
PubMed Identifier
16946226
Citation
Yang J, Cummings EA, O'connell C, Jangaard K. Fetal and neonatal outcomes of diabetic pregnancies. Obstet Gynecol. 2006 Sep;108(3 Pt 1):644-50. doi: 10.1097/01.AOG.0000231688.08263.47.
Results Reference
background

Learn more about this trial

Managing Diabetes During Pregnancy in the Wireless Age

We'll reach out to this number within 24 hrs